PhenoVista Biosciences

Executive Summary

PhenoVista Biosciences is a San Diego-based contract research organization (CRO) specializing in high-content imaging and phenotypic cell-based assays for preclinical drug discovery. Founded in 2014, the company leverages multiplexed imaging and machine learning to deliver quantitative biological data, serving biopharmaceutical clients in target validation, lead optimization, and mechanism-of-action studies. By combining advanced imaging technologies with AI-driven analysis, PhenoVista provides critical insights that accelerate the drug development pipeline, reducing time and cost for its partners. The company operates at the intersection of drug discovery and AI, positioning itself as a key enabler for the growing demand for phenotypic screening in early-stage research. As a private, pre-clinical-stage CRO, PhenoVista's growth is driven by expanding its service offerings and securing strategic partnerships with major pharmaceutical companies. The company's expertise in high-content imaging and machine learning differentiates it in a competitive CRO market, particularly as the industry shifts toward more complex, physiologically relevant assays. With the increasing adoption of phenotypic screening for challenging targets, PhenoVista is well-positioned to capture market share. While specific financial details are not publicly available, the company's sustained presence since 2014 and its focus on cutting-edge technologies suggest a stable business with growth potential. Upcoming catalysts include platform enhancements, new client wins, and expansion into adjacent service areas.

Upcoming Catalysts (preview)

• Q2 2026Launch of next-generation AI-powered image analysis platform70% success
• Q3 2026Major contract with top-20 pharmaceutical company50% success
• Q4 2026Expansion into in-vivo imaging services40% success